A Case of Squamous Cell Carcinoma in Nasal Cavity Treated with Conversion to Sirolimus in a Patient with Kidney Transplantation.
10.4285/jkstn.2014.28.2.83
- Author:
Tae Hyun RYU
1
;
Sung Hoo CHOI
;
Peel JUNG
;
Kang Hun LEE
;
Han Se KIM
;
Joon Seok OH
;
Seung Min KIM
;
Young Hun SIN
;
Joong Kyung KIM
Author Information
1. Department of Internal Medicine, Bong Seng Memorial Hospital, Busan, Korea. kidney119@hotmail.com
- Publication Type:Case Report
- Keywords:
Renal transplantation;
Sirolimus;
Squamous cell carcinoma;
Therapeutics
- MeSH:
Aged;
Calcineurin;
Carcinoma, Squamous Cell*;
Cyclosporine;
Drug Therapy;
Humans;
Immunosuppressive Agents;
Kidney Transplantation*;
Male;
Nasal Cavity*;
Quality of Life;
Sirolimus*;
Skin;
Skin Neoplasms
- From:The Journal of the Korean Society for Transplantation
2014;28(2):83-86
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Conversion of immunosuppressants to sirolimus, an inhibitor of mammalian target of rapamycin, is a useful treatment option for prevention of the adverse events of immunosuppressants such as calcineurin inhibitor in renal transplantation recipients. In addition, sirolimus has been improving the quality of life and increasing the survival of patients with renal transplantation by decreasing immunosuppression-related malignancies, particularly skin cancer. However, complete remission of skin squamous cell carcinoma after renal transplantation only by conversion to sirolimus has not been well reported, although its preventive effect on skin cancer is well known. We report on a 72-year-old male with squamous cell carcinoma in his nasal cavity consequent to renal transplantation, which was treated completely with the conversion of cyclosporine to sirolimus without surgical removal or chemotherapy.
